Revenue Recognition - Additional Information (Details) - USD ($)					1 Months Ended		12 Months Ended
	Dec. 07, 2020	Nov. 18, 2020	May 16, 2019	Nov. 14, 2017	Dec. 31, 2020	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Nov. 06, 2018
Disaggregation Of Revenue [Line Items]
Transaction price recorded in liabilities					$ 2,500,000		$ 2,500,000
Collaboration revenue							3,154,325	$ 3,458,331
Short-term research and development contract liability					6,681,025		6,681,025	4,097,443
Long-term research and development contract liability					1,937,575		1,937,575	4,017,894
Income tax expense							206,250	412,500
Prepaid expenses and other short-term assets					1,241,239		1,241,239	860,107
Other long-term assets					401,667		401,667	673,625
Amortization of Intangible Assets							11,666	11,667
Collaboration Agreement with Merck | Merck
Disaggregation Of Revenue [Line Items]
Up front non refundable payment				$ 2,500,000
Achievement of certain research and development milestones				120,000,000
Achievement of certain commercial milestones				150,000,000
Milestone payments received				2,500,000
Collaboration revenue							177,000	874,000
Short-term research and development contract liability					606,771		606,771	483,515
Long-term research and development contract liability					0		0	0
Collaboration Agreement with Merck | Merck | Maximum
Disaggregation Of Revenue [Line Items]
Eligible to earn achievement of certain research and development milestones				$ 101,000,000
First Amendment to Merck
Disaggregation Of Revenue [Line Items]
Milestone payments received		$ 300,000
Milestone payment associated with contract liability		$ 300,000
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences
Disaggregation Of Revenue [Line Items]
Milestone payments received	$ 1,250,000		$ 2,500,000
Milestone payment associated with contract liability	1,250,000		2,500,000
Collaboration revenue							2,978,000	$ 2,584,000
Short-term research and development contract liability					6,074,254		6,074,254
Long-term research and development contract liability					1,937,575		1,937,575
Equity investment nonrefundable upfront cash payment										$ 5,000,000.0
Equity investment for research collaboration agreement										5,000,000.0
Income tax expense	$ 206,250		$ 412,500
Collaboration Agreement with LG Chem Life Sciences | LG Chem Life Sciences | Maximum
Disaggregation Of Revenue [Line Items]
Additional amount receivable research development regulatory and sales milestones										$ 400,000,000
Einstein License And Service Agreement | Einstein
Disaggregation Of Revenue [Line Items]
License expenses					156,600	$ 313,000	907,600		$ 438,000
Prepaid expenses and other short-term assets					416,900		416,900
Other long-term assets					$ 0		0
Amortization of Intangible Assets							$ 490,700